NASDAQ · TLPHHealthcarePharmaceuticals

Talphera financials

$1.17−1.68%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
Revenue$28.0K$0.00
Gross profit$28.0K$0.00
Gross margin100.0%—
Operating income-$13.5M-$15.3M
Net income-$14.3M-$13.0M
Net margin−51035.7%—
Diluted EPS$-0.34$-0.50
EBITDA-$13.5M-$15.3M
Operating cash flow-$11.4M-$12.7M
Free cash flow-$11.4M-$12.7M
Diluted shares42.4M25.8M

Balance sheet

Period endDec 31Dec 31
Cash & equivalents$5.9M$8.9M
Short-term investments$14.5M$0.00
Total debt$0.00$0.00
Total assets$29.7M$18.2M
Total liabilities$12.7M$10.2M
Shareholders' equity$17.0M$8.0M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology